Assenagon Asset Management S.A. Decreases Holdings in Halozyme Therapeutics, Inc. $HALO

Assenagon Asset Management S.A. reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 70.4% during the first quarter, according to its most recent filing with the SEC. The fund owned 21,322 shares of the biopharmaceutical company’s stock after selling 50,763 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Halozyme Therapeutics were worth $1,378,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in HALO. Faithward Advisors LLC lifted its stake in Halozyme Therapeutics by 174.8% in the first quarter. Faithward Advisors LLC now owns 63,403 shares of the biopharmaceutical company’s stock valued at $4,098,000 after purchasing an additional 40,333 shares during the last quarter. Andina Capital Management LLC purchased a new stake in Halozyme Therapeutics in the first quarter worth $442,000. Campbell Newman Asset Management Inc. raised its stake in shares of Halozyme Therapeutics by 1.7% in the first quarter. Campbell Newman Asset Management Inc. now owns 36,130 shares of the biopharmaceutical company’s stock valued at $2,335,000 after buying an additional 603 shares during the period. Nations Financial Group Inc. IA ADV raised its stake in shares of Halozyme Therapeutics by 1.2% in the first quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company’s stock valued at $981,000 after buying an additional 183 shares during the period. Finally, Hsbc Holdings PLC lifted its position in shares of Halozyme Therapeutics by 1,202.4% during the 4th quarter. Hsbc Holdings PLC now owns 82,323 shares of the biopharmaceutical company’s stock valued at $5,584,000 after buying an additional 76,002 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on HALO shares. UBS Group reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the completion of the sale, the director directly owned 43,669 shares of the company’s stock, valued at approximately $2,891,324.49. The trade was a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 80,554 shares of company stock worth $5,562,746 in the last ninety days. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Down 1.6%

Shares of NASDAQ HALO opened at $77.01 on Thursday. Halozyme Therapeutics, Inc. has a 52 week low of $52.72 and a 52 week high of $82.22. The business has a 50-day simple moving average of $68.96 and a two-hundred day simple moving average of $69.23. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The company has a market cap of $9.13 billion, a P/E ratio of 27.70, a P/E/G ratio of 0.32 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.